Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled st
- jeanfrancoismaison
- May 19
- 1 min read
top of page
Search
Recent Posts
See Allhttps://pubmed.ncbi.nlm.nih.gov/40467521/
https://pubmed.ncbi.nlm.nih.gov/40450523/
https://pubmed.ncbi.nlm.nih.gov/40464483/
bottom of page
Comments